Quantcast
Last updated on April 20, 2014 at 1:20 EDT

Latest Glucokinase Stories

2008-09-25 09:00:16

Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes. The data showed that ARRY-403 demonstrated potent, highly glucose-blood-level dependent, control of both fasting and non-fasting glucose concentrations. Based on these and other results, Array plans to advance ARRY-403 into human clinical studies in the first half of 2009. The data were presented...

2008-09-03 12:00:06

Research and Markets (http://www.researchandmarkets.com/research/d99eac/competitor_analysi) has announced the addition of the "Competitor Analysis: Emerging Diabetes Drugs" report to their offering. Emerging diabetes drugs consider beta cell mass and function as an important target The next generation of diabetes drugs still is focused on metabolic approaches, but activities to preserve or even regenerate pancreatic islet cell mass and function are gaining momentum This...

2005-09-07 16:21:31

La Jolla, CA "“ In many patients with type 2 diabetes, the liver acts like a sugar factory on overtime, churning out glucose throughout the day, even when blood sugar levels are high. Scientists at the Salk Institute for Biological Studies discovered a key cellular switch that controls glucose production in liver cells. This switch may be a potential new target for the development of highly specific diabetes drugs that signal the liver to reduce the production of sugar. The Salk...